PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update

PolyPid Ltd. (NASDAQ:PYPD) was the recipient of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 8,900 shares, a growth of 111.9% from the August 15th total of 4,200 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily volume of 6,700 shares, the short-interest ratio is presently 1.3 days.

PolyPid Price Performance

NASDAQ PYPD traded down $0.12 during mid-day trading on Friday, hitting $3.47. The stock had a trading volume of 5,879 shares, compared to its average volume of 6,186. The company has a 50 day simple moving average of $3.57 and a 200 day simple moving average of $4.25. The company has a market cap of $16.62 million, a price-to-earnings ratio of -0.27 and a beta of 1.32. PolyPid has a 52-week low of $2.95 and a 52-week high of $9.20. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 1.95.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($1.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.26. Equities analysts forecast that PolyPid will post -4.39 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of PolyPid in a research report on Thursday, August 15th.

Hedge Funds Weigh In On PolyPid

A hedge fund recently bought a new stake in PolyPid stock. Rosalind Advisors Inc. acquired a new stake in PolyPid Ltd. (NASDAQ:PYPD) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 415,800 shares of the company’s stock, valued at approximately $1,913,000. PolyPid makes up 1.8% of Rosalind Advisors Inc.’s portfolio, making the stock its 20th biggest position. Rosalind Advisors Inc. owned about 8.67% of PolyPid at the end of the most recent quarter. 26.47% of the stock is owned by hedge funds and other institutional investors.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.